Background: Variations in testing for Clostridium difficile infection (CDI) may hinder patient care, increase
Introduction
Clostridium difficile is the major infective cause of nosocomial diarrhoea in the developed world. Rapid and accurate diagnosis is important to optimise patient care and infection prevention. 1 There has been an increase in the measured incidence of C. difficile infection (CDI) in countries with surveillance programmes, and a marked shift in epidemiology over the last decade. [2] [3] [4] In Europe C. difficile is the most commonly reported pathogen associated with hospital associated gastrointestinal disease, whilst in the US it was the most commonly reported health-care associated microorganism in a survey of 183 hospitals in 2010. 5, 6 In the most recent European epidemiological survey of CDI (2008) the incidence in 97 hospitals across 29
countries varied widely (range 0.0-36.3 per 10,000 patient bed days per hospital (PBH); weighted mean 4.1). 7 The reasons for this large variation are unclear. Predisposing factors to CDI, including increasing age, co-morbidities and use of broad-spectrum antibiotics may be similar across Europe, although exposure to different C. difficile strains likely varies. 1, 8 Notably, there was a >40-fold variation in CDI testing frequency across European countries, and a correlation between testing rate and reported infection rate was found. 7 Sub-optimal case ascertainment, either due to inadequate laboratory diagnosis or lack of clinical suspicion means that the true burden of CDI is unclear. [9] [10] [11] [12] A recent point prevalence study in Spain found that 66% of CDI patients on a single day were undiagnosed or misdiagnosed, due either to lack of clinical suspicion (47%) or inadequate laboratory testing (19%). 9 Optimal laboratory diagnosis of CDI depends on testing the right patients, at the right time with the right tests. Importantly, detection of C. difficile toxin in patient faecal samples, as opposed to toxigenic C. difficile (strains that produce toxin in vitro, or have toxin genes present), correlates with disease severity and mortality. 12, 13 To improve the sub-optimal sensitivity of commercially available toxin detection assays, two-stage laboratory diagnosis, involving a sensitive C. difficile screening test followed by a C. difficile toxin assay is recommended. 1, 12 Nevertheless, a questionnaire-based study in 125 European laboratories in 2010 showed wide variation in use of CDI diagnostic methods, with a quarter still using a single assay. 14 Notably, however, such data do not ascertain the true extent of missed CDI diagnoses.
We aimed to determine the under-ascertainment of CDI in hospitals in 20 European countries by asking participating hospitals (PHs) to forward diarrhoeal in-patient faecal samples, regardless of microbiology tests requested or performed locally, received on two days (one in winter 2012/13 and one in summer 2013) to a national coordinating laboratory (NCL) for CDI testing by the study reference method (SRM). PHs were also asked to complete a study questionnaire regarding CDI testing.
Methods

Study design
The study followed the design of a previous point-prevalence study conducted in Spain. 9 Ethical approval was granted in the Netherlands, Sweden and Slovenia; the remainder did not require ethical approval as the study was classed as surveillance. Results were reported back to participating laboratories but (purposely) not in a clinically relevant timescale i.e. (a minimum of 3 weeks after receipt of sample). The -PHs were recruited at a rate of one per one million population for each of the 20 study countries, and were selected by national co-ordinators to cover all major geographical regions within each country. The full study design is shown in the study flow chart (figure 1.)
Study questionnaires
Details of testing policy and methods and CDI testing and positivity rates for each PH during two 12 month 
Samples
All in-patient diarrhoeal samples submitted to the PH microbiology laboratory on the study days were eligible for inclusion, regardless of the original test(s) requested. There was no age exclusion but only one sample per patient was included. Samples were anonymised by the PH using a EUCLID study number and sent with a data capture form to the EUCLID National Coordinating Laboratory (NCL) for their country; patient age, gender and specialty, and whether the sample was tested for CDI at the PH and the result of any such test were recorded. Samples were stored at 4°C before transport to the NCL within 7 days.
Transport was refrigerated for 6 countries in the winter sampling period and for all 20 in the summer. 
Testing at the NCLs
Data analysis
All PH and NCL data were entered onto a secure online system. Using questionnaire data, mean testing and CDI rates/10,000 patient bed days (PBD) (synonymous with occupied bed days) were calculated for each country and Europe. Also, the measured rates on the EUCLID study days were calculated using the number of tests performed, cases detected by NCLs and the PBDs of each PH that year. For testing methodology, an optimised diagnostic algorithm was defined as GDH or NAAT followed by (or simultaneous with) toxin detection.
Patients with samples that were CDI positive at the NCL (GDH positive/toxin positive by SRM), but not PH -samples with positive SRM at the NCL but negative results at the PH (false-negatives) or samples with negative SRM results at the NCL but positive at the PH (falseResults of the confirmatory tests were used to provide additional information on the SRM result but did not change this, as none of the confirmatory assays directly detected toxin in faeces.
All data were analysed on SPSS version 19. Differences in proportions were compared using Mann-Whitney M N For comparisons across European regions, countries were categorised geographically according to a UN classification. 16 Correlations between testing rates and CDI case rates, and testing rates and the prevalence of ribotype 027 P
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Results
Submitted samples
Under-diagnosis and misdiagnosis
Across the 481 European hospitals on the two study days, 148 (mean 74) patients with CDI (GDH positive/toxin positive using SRM at NCLs) were not tested for CDI at the PH ( C. difficile toxin was detected using SRM in samples from 68 patients (mean 34, 1.6%) who had originally received a negative test result at the PH (false-negatives). Of these, 52/68 were confirmed as toxigenic C.
difficile (12 by toxigenic culture, 40 by culture/PCR). The UK had the highest proportion of PHs using an optimised method for CDI diagnosis, and had low levels of both false-positive and false-negative results (table 2) . Overall, only 57.2% of the patients tested for CDI across Europe during the study had a diagnosis at their original PH that agreed with the SRM as performed at NCLs.
CDI testing and case rates Reported versus measured CDI testing and case rates
Of 481 PHs, 458 reported (via questionnaires) their testing and CDI case rates per 10,000 patient bed days (PBD) (table 3), providing data for 19/20 countries; neither PHs in Slovenia provided this information. There was a 48-fold variation in country specific CDI testing rates (4.6-223.3/10,000 PBD). The reported CDI rates also varied markedly (41-fold variation) between countries (mean 6.6-7.3; 0.7-28.7 cases/10,000 PBD).
Country reported rates were generally similar comparing 2011/12 with 2012/13, but these approximately doubled in Finland, Ireland and Romania, whilst there was an 80% decrease in Slovakia.
The measured CDI rate during the study (by NCLs) was 2.4-2.9-fold higher than the reported rate (mean 17.2-19 vs 6.6-7.3 cases/10,000 PBD, respectively). The measured testing rate was 1.3-1.5-fold higher than the reported rate (mean 92.4-95.4 vs 62.3-69.2/10,000 PBD, respectively) (table 3) . There was a poor correlation between the rate of testing and CDI rate regardless of whether the rates were reported or measured (P R 2 = 0.2302 and 0.353, respectively) (figures2a and 2b).
Testing policy and methodology
In 2011-12 (questionnaire 1) of 481 hospitals, 468 routinely tested for CDI; the 14 exceptions comprised 3 and 11 hospitals in Bulgaria and Romania, respectively (table 4a) . In 2012-13 (questionnaire 2) 427/438 hospitals that replied routinely tested for CDI; again the exceptions were in Bulgaria and Romania (table   4b) . Of the PHs routinely testing for CDI, 9.6% (11.3% and 7.5% in questionnaire 1 and 2, respectively) examined all submitted diarrhoeal in-patient samples (empirical testing); 24.5% tested all in-patient diarrhoeal samples if other criteria were met, such as patient >2 years old or in hospital for >3 days (tables 4a and 4b). UK PHs reported the highest level of empirical testing (18%), while 62.4% and 63.2% of PHs and 20% and 30% of European countries only tested for CDI if there was a specific clinician request (questionnaires 1 and 2, respectively).
In 2011-12 there were 152 PHs (32.5%) using optimised methods for CDI laboratory diagnosis, with the UK accounting for 28.9% of these (n = 44) (table 4a); the overall rate increased to 48.0% in 2012-13
M N PH ing data in both questionnaires, p = <0.00001) (table4b). A toxin detection method was used by 75.6% and 72.8% of PHs, while few employed stand-alone molecular tests (mean 4.2% across both questionnaires). The largest change in methodology occurred in Czech Republic, where 90% of the PHs changed from SAT assays to an optimised diagnostic method.
PCR-ribotypes
There were 138 different C. difficile ribotypes isolated among 1211 isolates; the ten most common are shown in figure 3 . C. difficile ribotype 027 was the most prevalent, but 88% of these were found in only 4/20 countries: Germany (43.5% of all 027s), Hungary (17.5%), Poland (16.1%) and Romania (11.7%). An inverse correlation was observed between testing rate and prevalence of ribotype 027 across north, south, E P -0.6996) (figure 4).
Quality assurance
EQA results were obtained for all NCLs. All cell-cytotoxicity results were correct; one NCL had an incorrect culture result for 2/12 of their EQA samples (overall NCLs 2/240) and one had an incorrect result using the
C. DIFF QUIK CHEK COMPLETE® (overall 1/240). PCR results were slightly more variable, with 4 NCLs
returning a false-negative result for 1/12 (overall 4/240) EQA samples.
Discussion
In the largest international epidemiological study of CDI diagnosis ever performed, we found that underreporting across Europe was common, driven primarily by a lack of clinical suspicion (and hence no local testing for CDI), and was compounded by misdiagnosis related to sub-optimal testing. On one day across Europe, a mean of 74 in-patients with CDI were not tested for CDI by their hospital; on average a further 34 patients had a false-negative result at the local hospital (table 2 and supplementary materials table 2 ).
Assuming that our measured daily under-and mis-diagnosis rates were constant, these figures equate to approximately 40,000 missed CDI diagnoses per year at the 481 study hospitals across Europe. The total number of patients with under-or mis-diagnoses in the European Union would be far greater than this estimate, especially considering that there are approximately 8000 hospitals in the region. 17 Notably, the median age of the 148 undiagnosed patients was significantly lower than that of the 426 patients with CDI who were tested at PHs (72 versus 76 years, p= <0.0001). Our data suggest that clinical suspicion of, and therefore testing for CDI is affected by patient age, potentially exaggerating the differences between agespecific diagnosis rates. In the UK, where CDI testing is relatively common, the age specific CDI rate in those aged >75 years (172.9 per 100 population) is 3.5-and 7.2-fold greater than in those aged 65-74 years and the total population, respectively. 18 The rate of CDI under-diagnosis (23.1%) we found is similar to that recorded in Spain (25%) in 2009. 9 Unlike the previous study, however, we only collected one sample per patient, thereby reducing the effect of repetitive sampling. We did not determine why a sample was not tested, and so our measured underdiagnosis rate may be inflated. For example, it is the policy in many hospital laboratories not to re-test previously diagnosed patients (e.g. those positive within 14 days), even if a repeat sample is submitted.
However, as current CDI laboratory tests are not indicated for treatment monitoring, the number of samples from known CDI positive patients sent to the laboratory is likely to have been small. 1 Conversely, the rate of under-diagnosis could potentially be higher, as we have no indication of the number of patients who had no faecal samples collected due to lack of clinical suspicion of infection, or empirical treatment without attempted laboratory diagnosis.
European guidelines state that if free toxin in faeces is absent but C. difficile is detected (bacterium, toxin gene or GDH) then CDI cannot be differentiated from asymptomatic colonisation. 1 Therefore, detection of a C. difficile target in the absence of free toxin could be defined as a false-positive result. In our study 237 patients had faecal samples that were designated positive for CDI at the PH (by local definitions) but tested negative by SRM at the NCL (table 2) . If, however, we re-designated the 136/237 cases that had a toxigenic C. difficile strain isolated (at the NCL) as true-positives for CDI, this would reduce the false-positive rate from 5.2% to 2.2%. Notably, the majority (65%) of these 136 cases were not tested for free toxin at the original PH, even though locally they were considered to represent CDI (68 PCR and 21 cytotoxigenic culture). Whichever is considered the gold-standard testing method for CDI, 12,19 the frequency of misdiagnoses was dwarfed by the undiagnosed rate (20.4%). Patients with a false-positive result may receive unnecessary treatment and/or inappropriate isolation measures (single room or cohorting).
Inappropriate isolation can block scarce resources, with unforeseen consequences due to failure to isolate other patients, while cohorting could expose (non-genuine CDI) patients to real CDI cases. It remains unclear whether C. difficile positive but toxin-negative cases are a major source of cross-infection. 20 The diagnostic method used in our study (QUIK CHEK COMPLETE, Techlab, US) was chosen as toxin detection in faecal samples correlates with clinical outcome, whilst detection of a toxigenic strain does not. 12, 13 Toxin detection is therefore a better indicator of clinically relevant CDI. Our false-negative rate was much lower (1.6% vs. 19.0%) compared with a previous study, but this used toxigenic culture to determine CDI status, which will over-estimate clinically relevant CDI. 9, 12 The toxin detection method we used could be criticised as it is not the most sensitive method. 11 It was, however, the only commercial method that could be distributed to all 20 study countries. Refrigerated transport of samples was universal following the summer but not the winter study day (n=6/20 NCLs). It is known that C. difficile toxins can degrade at room temperature, and so some samples reported as toxin-positive by PHs and yet toxin-negative at NCLs could have been wrongly designated as false-positives. 21 However, as this phenomenon could only affect laboratories using a toxin detection method, it may only be relevant for 41/237 (17%) false-positive results.
The only time non-refrigerated transport was used during this study was during winter, which may have helped mitigate the potential for toxin degradation.
Other limitations to our study include the possible introduction of bias regarding testing at PH (i.e. we may have unintentionally altered practice on the study days). Notably, the highest testing rate at PHs for samples submitted on the study days was in the Czech Republic (97.8%), even though empirical testing is uncommon here (table 2) . This suggests either potential bias, or that the level of clinical suspicion in some countries is relatively high. In support of the latter, no empirical testing was recorded in study hospitals in
Bulgaria, and in turn only 35.1% of submitted samples had a CDI test at PHs, which is consistent with a low level of clinical suspicion of CDI. This potential bias of increased testing on the study day may also account for the increased measured incidence of CDI (2.4-2.9-fold) compared with the questionnaire-reported rate (table 3) . Interestingly, however, the measured testing incidence was only 1.3-1.5-fold higher than the reported rate, indicating only a moderate level of increased testing. We made several assumptions when calculating the annual measured rates, including that bed occupancy and testing rates were constant throughout the year. Additionally, the measured rate could not be calculated for 14% of NCLs because of missing data.
The reported CDI testing frequency across Europe for 2011-12 has increased from that recorded in 2008 (65.8 vs 52.1 tests/10,000 PBD). 7 There has also been a 70% increase in reported CDI incidence from 4.1 to 7.0 CDI cases/10,000 patent bed days, despite the frequent use of sub-optimal laboratory diagnostics. 7 It should be noted, however, that CDI E 87 hospitals compared with 427-468 in the present study. 7 Importantly, if cases diagnosed at NCLs are used to calculate CDI incidence, the is 2.4-2.9-fold higher than the reported CDI rate (table 3) .
The diversity of C. difficile ribotypes across Europe was much greater in EUCLID compared with the 2008 study (138 ribotypes from 20 countries vs 65 from 26 countries, respectively). 7 Additionally, the overall prevalence of ribotype 027 has increased more than 3-fold (5% to 18%), although there is marked intercountry variation; high ribotype 027 endemicity has shifted from the UK and Ireland in 2008 to Germany and eastern Europe in 2012/13. 7 Notably, we found an inverse correlation between rate of CDI testing and C. difficile 027 prevalence in four regions of Europe (P figure 4 ). This suggests that increased CDI awareness, using optimal testing policies and methodologies, can reduce the dissemination of epidemic strains. Given the increased morbidity and mortality associated with CDI caused by hypervirulent strains such as ribotype 027, this is an important observation that reinforces the potential clinical and epidemiological value of high CDI testing rates. It has been reported that CDI testing rates correlate with reported case rates. 7 We found only a week association between these parameters (Figures 2a (reported rates) and 2b (measured rates) R 2 =0.2302 and P ), which is likely due to the much larger study and increased heterogeneity of sampling and testing policies. Changes to sampling and testing policy and methodology clearly affect CDI positivity rates. 22, 23 In the UK there has been a national campaign to reduce the incidence of CDI and to standardise laboratory diagnosis. 24 The proportion of UK PHs using methodology consistent with the SRM was the highest of all countries, in line with national guidelines;
consequently, under-and misdiagnosis was relatively uncommon. This perhaps serves as an example of how improved monitoring of CDI can help to reduce infection rates. While national surveillance schemes have been associated with reduced incidence of CDI in some countries, this remains a major healthcare burden. [23] [24] [25] [26] [27] Our study highlights the large variation and inconsistencies in the diagnosis of CDI across Europe. Many surveillance systems rely on the reported rate of CDI without taking into consideration the underlying diagnostic methods. 5, 29, 30 CDI diagnosis should be standardised to ensure that data within and between countries can be meaningfully compared, and so that prevention and control resources are directed appropriately.
Research in context
T -centre study that collected data on C. difficile infection (CDI) in hospitalised patients, and gave details of methods of diagnosis and incidence. 7 All data were collected via questionnaire with no secondary examination of faecal samples carried out. This study could therefore not CDI Interpretation: Our study, using a population-adjusted, hospital sample size that is 5 times larger than the Table showing the patient demographics for all samples and samples found positive for CDI at the National Coordinating Laboratory (NCL) using the optimised method and the confirmation method. SRM = Study reference method. ITU = Intensive treatment unit. HDU = High dependency unit. Table shows the number of samples sent from local hospitals to national coordinating laboratories and the percentage of those that had a test at the submitting Participating Hospital (PH) before submission. The percentage of all the samples which were positive for CDI at the National Coordinating Laboratory (NCL) (using the Study reference method (SRM)) which never received a test are indicated as under-diagnosed. Those which had incorrect results given at the original local hospital when compared with the Study reference method (SRM ) result at the NCL are indicated as misdiagnosis. This table shows the combined data from winter and Summer sampling periods. The full data set can be found in Supplementary materials table 2. Table showing the CDI testing and CDI case rates per 10,000 patient bed days found in both of the EUCLID study questionnaire periods (2011-2012 and 2012-2013) as reported by the participating hospitals (PHs) from each study. The EUCLID measured rate was calculated using the actual number of cases or tests performed on the study day and the patient bed days supplied for each participating hospital for that year. Tested all in-patient samples only if they met certain criteria (which varied at different hospitals), these included patient >2 years old, patient hospitalised >3 days, query antibiotic-associated diarrhoea. b Optimised testing defined as detection of GDH and C. difficile toxins directly from a faecal sample, either using a combined method or algorithm approach. c Includes stand-alone toxin EIAs and toxigenic culture Tables showing numbers of participating hospitals (PHs) in each country and the percentage that reported testing all diarrhoeal faecal samples (empirical testing) in the two questionnaires. Testing methodology is indicated as those that use an optimised method, stand-alone molecular method or some form of detection of C. difficile toxins from faecal samples. 
